(19)
(11) EP 4 388 013 A1

(12)

(43) Date of publication:
26.06.2024 Bulletin 2024/26

(21) Application number: 22859446.1

(22) Date of filing: 22.08.2022
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 35/00; C07K 16/2878; C07K 2317/75; C07K 2317/73; C07K 2317/34; A61K 2039/505
(86) International application number:
PCT/US2022/075301
(87) International publication number:
WO 2023/023677 (23.02.2023 Gazette 2023/08)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 20.08.2021 US 202163235445 P

(71) Applicant: University of Virginia Patent Foundation
Charlottesville, VA 22903 (US)

(72) Inventors:
  • TUSHIR-SINGH, Jogender
    Davis, CA 95616 (US)
  • BHATNAGAR, Sanchita
    Davis, CA 95616 (US)

(74) Representative: Isarpatent 
Patent- und Rechtsanwälte Barth Hassa Peckmann & Partner mbB Friedrichstraße 31
80801 München
80801 München (DE)

   


(54) STRATEGY FOR HIGHLY SUPERIOR DR5 ACTIVATION INCLUDING IN TUMORS AND CANCERS